Fast ventricular tachycardias in patients with implantable cardioverter-defibrillators: Efficacy and safety of antitachycardia pacing A prospective and randomized study by Jiménez-Candil, Javier et al.
RT
v
c
o
s
u
s
n
o
d
d
r
h
m
F
p
V
m
m
t
a
s
v
T
a
s
a
o
s
i
i
i
d
c
f
S
b
m
d
d
r
a
(

F
w
w
Journal of the American College of Cardiology Vol. 45, No. 3, 2005
© 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00
PCORRESPONDENCE
esearch Correspondence
Fast Ventricular Tachycardias in Patients With Implantable Cardioverter-Defibrillators:
Efficacy and Safety of Antitachycardia Pacing
ublished by Elsevier Inc.A Prospective and Randomized Study
r
s
a
e
n
s
f
i
2
o
s
A
i
n
i
w
b
A
H
t
H
F
f
a
a
o
s
T
A
M
L
H
N
Mo the Editor: Between 11% and 40% of detected monomorphic
entricular tachycardias (VTs) in patients with implantable
ardioverter-defibrillators (ICDs) have a cycle length (CL)
f 320 ms (1,2). Antitachycardia pacing (ATP) and high-energy
hocks (HES) are available for the treatment of these fast ventric-
lar tachycardias (FVTs). High-energy shocks commonly are
elected because the efficacy and safety of ATP in this setting have
ot been extensively proven and because a short CL is a predictor
f unsuccessful therapy and acceleration (3,4). Nevertheless, the
isadvantages of HES are battery drain, VT termination delay, and
eterioration of quality of life (5). Although ATP has been
eported to terminate as many as 80% of FVT episodes, studies
ave indicated that frequent, nonsustained FVT might overesti-
ate the efficacy of ATP (1). To determine the effect of ATP in
VT treatment, we compared the HES incidence with ATP
rogrammed on versus off. We also analyzed the impact of ATP in
T duration and VT-associated symptoms.
All patients with ICDs who presented with sustained mono-
orphic VT previously recorded or at risk of presenting mono-
orphic VT (ischemic heart disease, arrhythmogenic right ven-
ricular dysplasia, and dilated cardiomyopathy) were enrolled after
written informed consent was obtained. Patients with long QT
yndrome, Brugada syndrome, or hypertrophic cardiomyopathy at
ery low risk of presenting with monomorphic VT were excluded.
wo programming strategies in the FVT zone were compared in
multicenter, prospective, randomized, and single-blind crossover
tudy. Strategy A consisted of two ATP bursts followed by HES,
nd strategy B consisted of HES only. Patients were assigned to
ne strategy for six months and then crossed over to the other
trategy for another six months. The primary end point was the
ncidence of HES; secondary end points were VT duration and
ncidence of syncope/near-syncope.
Only FVT detection and therapy programming was standard-
zed. The detection of FVT was based on heart rate criteria and
efined for a CL of 260 to 310 ms. Strategy A consisted of two
onsecutive bursts of five and eight pulses at 84% of VT CL,
ollowed by maximum HES; strategy B consisted of HES alone.
uccessful ATP was defined as tachycardia terminating during the
urst or within four beats after the burst if the VT CL was
odified by ATP. The VT acceleration was defined as VT CL
ecreasing more than 10% immediately after ATP therapy.
Statistical analysis was performed using SPSS 11.5 for Win-
ows (SPSS Inc., Chicago, Illinois). Assuming an ATP success
ate of 77%, we estimated a sample size of 125 patients to detect
difference of 75% on HES incidence, statistical power of 80%
10% expected incidence of FVT in each strategy and alpha
0.05). The two-tailed Student t test and the chi-square test or
isher exact test were used when appropriate. Multivariate analysis
as performed by logistic regression method. A p value of 0.05
as considered statistically significant.
We randomly assigned all 137 eligible patients. One patient Aeceived a heart transplant for heart failure during the first assigned
trategy (strategy B), and three other patients died during their first
ssigned strategy: one suddenly in strategy A at one week after
xtensive percutaneous coronary revascularization (electrograms
ot available) and two in terminal heart failure (one in each
trategy); no FVT were recorded.
This analysis focuses on the 133 patients who finished the
ollow-up (65 in the treatment order strategy A-strategy B and 68
n strategy B-strategy A) (Table 1). Forty-nine FVTs occurred in
2 patients (17%), with a mean CL of 286 16 ms. Twenty-seven
ccurred in 10 patients in strategy A and 22 in 13 patients in
trategy B. One patient presented with FVT in both strategies.
ntitachycardia pacing terminated 24 of 27 FVTs (efficacy, 89%),
n all cases with the first burst. In strategy B, there were two
on-sustained FVTs that terminated spontaneously during charg-
ng. The remaining FVTs in strategy B and the three FVTs that
ere unsuccessfully treated by ATP in strategy A were terminated
y the first program of HES. Only one episode of FVT in strategy
was accelerated. The use of strategy A significantly reduced the
ES incidence in the FVT zone (3 vs. 20, p  0.001), as well as
he proportion of patients with HES for FVT and the mean of
ES for FVT per patient. Strategy A reduced the duration of
VT episodes and reduced the incidence of syncope/near-syncope
or FVT (Table 2). A longer CL (289 16 vs. 280 0; p 0.01)
nd beta-blocker treatment (50% vs. 4.3%; p  0.04) were
ssociated with a higher ATP efficacy by logistic regression.
This is the first randomized study designed to evaluate the effect
f ATP in FVT treatment in patients with ICD. Our results
uggest that a single, short ATP burst reduces the HES incidence
able 1. Baseline Clinical Characteristics at Enrollment
Characteristics Value
ge (yrs) 64  11
ale gender (%) 71 (86.5)
eft ventricular-ejection fraction (% 0.30) 36  13 (49.6)
eart disease (%)
Coronary artery disease 96 (72.1)
Idiopathic dilated cardiomyopathy 16 (12.1)
No structural heart disease 8 (6.1)
Arrythmogenic right ventricular dysplasia 6 (4.5)
Valvular disease 5 (3.7)
Other 2 (1.5)
YHA functional class (%)
I 66 (46.8)
II 57 (40.4)
III 10 (7.2)
edications (%)
ACE inhibitors 102 (76.7)
Beta-blockers 98 (69.5)
Amiodarone 20 (14.5)
Sotalol 6 (4.5)CE  angiotensin-converting enzyme; NYHA  New York Heart Association.
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February 1, 2005:460–9n the FVT zone and may improve the clinical tolerance of these
achycardias.
In re-entrant VT, the ability of ATP to terminate the arrhyth-
ia depends on the presence of an excitable gap (6) and on the
apability of the impulses to penetrate this gap. The main limiting
actor for penetrating the excitable gap is the distance to the
ircuit; therefore, a long burst or a short-pacing CL is needed to
each the FVT circuits. The first burst that we selected was shorter
nd faster than those previously reported; nevertheless, the efficacy
nd acceleration rate were similar, suggesting that the shorter CL
ight compensate for a lower number of beats in the initial ATP
rain (1). This observation may be important to decrease the delay
efore the rescue HES is delivered if needed.
The number of FVTs is lower than in previous studies; however,
he proportion of patients with FVT is similar. The high propor-
ion of patients treated with beta-blockers and the inclusion of
onischemic patients may explain this difference. The use of ATP
lso appears to reduce the incidence of syncope/near-syncope
ssociated with an episode of FVT, presumably as a result of a
eduction in the VT duration. Interestingly, beta-blockers in-
reased the efficacy of ATP, indicating a possible influence of
utonomic tone in the maintenance of the VT (7,8).
This study suggests that a single, short ATP burst is efficient
nd safe for the treatment of FVT, reducing the HES incidence
nd arrhythmia-related symptoms. Nevertheless, the small number
f episodes and patients limits the power of these conclusions and,
herefore, a larger prospective study is required to validate these
ata.
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able 2. Analysis of Events per Patient
Variable Strategy A
umber of patients with FVT (%) 10 (7.5)
ean of FVT per patient 0.20  1.01
umber of patients with HES secondary to
FVT (%)
2 (1.5)
ean of HES per patient secondary to FVT 0.02  0.12
ES/FVT (%) 3/27 (11)
VT episode duration, s (range) 9.3  8.4 (5–40) 1
yncope for FVT (%) 2/27 (7.4)*
ear-syncope for FVT (%) 1/27 (3.7)
yncope/near-syncope for FVT (%) 3/27 (11)
ean CL 288  15
The two episodes of syncope in strategy A occurred secondary to fast VT unsucces
CI  confidence interval; CL  cycle length; FVT  fast ventricular tachycardiaSimvastatin Improves Endothelial Function
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1997;80:1487–9.in Patients With Rheumatoid Arthritiso the Editor: Rheumatoid arthritis (RA) is the most common
ystemic connective tissue disease and affects 2.1 million people in the
.S., 1.5 million of whom are women (1). Patients with RA are at
ncreased risk of developing premature cardiovascular disease, whichationale for preventive measures at an early stage before overt
ardiovascular disease becomes evident. Interestingly, endothelial
ysfunction, the key event in early atherogenesis, just recently has
een described in patients with RA both with high and low diseaseSt
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